Cannabidiol (CBD) has previously been shown to inhibit inflammatory cytokine production in both in vitro and in vivo studies of neurodegenerative diseases. To date, the CBD treatment of these diseases by quantitative targeting directly to the brain is one of the greatest challenges. In this paper, we present a new particulate system capable of delivering CBD into the brain via the intranasal route.
View Article and Find Full Text PDFThis report presents a nanoparticulate platform for cannabidiol (CBD) for topical treatment of inflammatory conditions. We have previously shown that stabilizing lipids improve the encapsulation of CBD in ethyl cellulose nanoparticles. In this study, we examined CBD release, skin permeation, and the capability of lipid-stabilized nanoparticles (LSNs) to suppress the release of IL-6 and IL-8.
View Article and Find Full Text PDFWe have developed an ethyl cellulose-based nanoparticulate system for encapsulation of sparingly soluble active pharmaceutical ingredients. Cannabidiol (CBD) and curcumin (CUR) were selected as model active ingredients. Using the nanoprecipitation method, nanoparticles ranged between 150 nm and 250 nm were obtained with an entrapment efficiency of >80%.
View Article and Find Full Text PDFIntroduction: Israel hosts documented labor migrants (DLM), and recently also undocumented migrants (UDM), mostly from Horn of Africa. This study aims to compare treatment outcomes and other clinical aspects between a sample of 154 DLM and 113 UDM who were treated in two tuberculosis clinics between 2005 and 2010.
Results And Discussion: Compared to DLM, UDM were younger males, stayed in Israel for shorter periods, had lower coverage of medical insurance, were less likely to be employed, and had greater difficulties in communication with the medical staff.